{"id":"gemcitabine-plus-ts-1","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (neutropenia, thrombocytopenia)"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Hand-foot syndrome"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Gemcitabine is a nucleoside analog that inhibits ribonucleotide reductase and gets incorporated into DNA, causing chain termination and apoptosis. TS-1 is an oral fluoropyrimidine combination (tegafur, gimeracil, oteracil) that inhibits thymidylate synthase and enhances fluorouracil activity. Together, they provide synergistic cytotoxic effects against cancer cells with complementary mechanisms of action.","oneSentence":"Gemcitabine plus TS-1 is a combination chemotherapy regimen that inhibits DNA synthesis and disrupts nucleotide metabolism to kill rapidly dividing cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:13:55.133Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pancreatic cancer"},{"name":"Gastric cancer"},{"name":"Biliary tract cancer"}]},"trialDetails":[{"nctId":"NCT04172402","phase":"PHASE2","title":"NGS as the First-line Treatment in Advanced Biliary Tract Cancer","status":"COMPLETED","sponsor":"National Health Research Institutes, Taiwan","startDate":"2019-12-27","conditions":"Advanced Biliary Tract Cancer","enrollment":48},{"nctId":"NCT05065957","phase":"PHASE2, PHASE3","title":"Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer","status":"RECRUITING","sponsor":"InnoPharmax Inc.","startDate":"2022-03-29","conditions":"Biliary Tract Cancer","enrollment":180},{"nctId":"NCT03252808","phase":"PHASE1","title":"Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients with Unresectable Pancreatic Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takara Bio Inc.","startDate":"2017-09-25","conditions":"Pancreatic Cancer Stage III, Pancreatic Cancer Stage IV","enrollment":36},{"nctId":"NCT06331845","phase":"PHASE2","title":"Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2024-05-01","conditions":"Metastatic Nasopharyngeal Carcinoma, Intermittent Systematic Chemotherapy","enrollment":39},{"nctId":"NCT03559348","phase":"PHASE2","title":"Locally Advanced or Metastatic Pancreatic Adenocarcinoma","status":"COMPLETED","sponsor":"National Health Research Institutes, Taiwan","startDate":"2018-04-03","conditions":"Pancreatic Adenocarcinoma","enrollment":49},{"nctId":"NCT00429858","phase":"PHASE2","title":"Gemcitabine and S-1 for Locally Advanced Unresectable or Metastatic Pancreatic Cancer","status":"TERMINATED","sponsor":"Andrew Ko","startDate":"2007-01-22","conditions":"Pancreatic Cancer","enrollment":21},{"nctId":"NCT02425137","phase":"PHASE2","title":"A Study of S-1 in Combination With Gemcitabine as First-Line Treatment in Patients With Advanced Biliary Tract Cancer","status":"COMPLETED","sponsor":"TTY Biopharm","startDate":"2015-04","conditions":"Advanced Biliary Tract Cancer(BTC)","enrollment":51},{"nctId":"NCT02182778","phase":"PHASE3","title":"GEM/Cisplatin/S-1 vs GEM/Cisplatin for Biliary Tract Cancer","status":"COMPLETED","sponsor":"Kansai Hepatobiliary Oncology Group","startDate":"2014-07-09","conditions":"Biliary Tract Cancer","enrollment":246},{"nctId":"NCT01821248","phase":"PHASE2","title":"A Phase II Trial of Preoperative Chemotherapy for Biliary Tract Cancer (BTC) With Node Metastasis","status":"UNKNOWN","sponsor":"Kansai Hepatobiliary Oncology Group","startDate":"2013-07-23","conditions":"Biliary Tract Cancer","enrollment":25},{"nctId":"NCT01430052","phase":"PHASE2","title":"Chemoradiotherapy With Gemcitabine/S-1 vs Gemcitabine/S-1 for Locally Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Osaka Medical Center for Cancer and Cardiovascular Diseases","startDate":"2009-04","conditions":"Pancreatic Cancer","enrollment":110},{"nctId":"NCT01713387","phase":"PHASE1","title":"A Phase I Study of Adjuvant Chemotherapy With GS in Biliary Tract Cancer Undergoing Resection Without Major Hepatectomy","status":"COMPLETED","sponsor":"Kansai Hepatobiliary Oncology Group","startDate":"2012-04","conditions":"Biliary Tract Cancer","enrollment":38},{"nctId":"NCT01693419","phase":"PHASE2","title":"S-1, Gemcitabine and Erlotinib for Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Hallym University Medical Center","startDate":"2011-08","conditions":"Pancreas Neoplasms","enrollment":37},{"nctId":"NCT01946646","phase":"PHASE1","title":"Phase I Study of TS-1 With Concurrent Radiotherapy to Treat Pancreatic Cancer","status":"TERMINATED","sponsor":"National Taiwan University Hospital","startDate":"2013-10","conditions":"Metastatic Pancreatic Cancer","enrollment":10},{"nctId":"NCT02754180","phase":"PHASE2","title":"Adjuvant Gemcitabine Versus Gemcitabine With Chemoradiation in Pancreatic Adenocarcinoma With R1 Resection and/or Positive Lymph Nodes","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2016-03","conditions":"Pancreatic Neoplasms","enrollment":110},{"nctId":"NCT01284413","phase":"PHASE1, PHASE2","title":"Gemcitabine/Cisplatin/S-1(GCS) Combination Therapy for Patients With Advanced Biliary Tract Cancer","status":"COMPLETED","sponsor":"Kansai Hepatobiliary Oncology Group","startDate":"2010-12","conditions":"Biliary Tract Cancer","enrollment":68},{"nctId":"NCT02146703","phase":"PHASE2","title":"Gemcitabine and S-1 for Advanced Biliary Tract Cancer","status":"COMPLETED","sponsor":"Hallym University Medical Center","startDate":"2005-08","conditions":"Biliary Tract Neoplasm","enrollment":38},{"nctId":"NCT01171755","phase":"PHASE2","title":"Phase II Study of Gemcitabine and TS-1 in Biliary Trat Cancer","status":"TERMINATED","sponsor":"Samsung Medical Center","startDate":"2008-02","conditions":"Biliary Tract Cancer","enrollment":19},{"nctId":"NCT00498225","phase":"PHASE3","title":"Phase III of Gemcitabine Vs TS-1 Vs Gemcitabine Plus TS-1 in Pancreatic Cancer","status":"COMPLETED","sponsor":"Taiho Pharmaceutical Co., Ltd.","startDate":"2007-07","conditions":"Pancreatic Cancer","enrollment":834},{"nctId":"NCT00436423","phase":"PHASE2","title":"A Phase Ⅱ Study of Gemcitabine Combination With TS-1 in Patient With Advanced or Recurred Pancreatic Cancer","status":"COMPLETED","sponsor":"Korea University Anam Hospital","startDate":"2006-03","conditions":"Pancreatic Neoplasm, Neoplasm Metastasis","enrollment":38}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Gemcitabine plus TS-1","genericName":"Gemcitabine plus TS-1","companyName":"Taiho Pharmaceutical Co., Ltd.","companyId":"taiho-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Gemcitabine plus TS-1 is a combination chemotherapy regimen that inhibits DNA synthesis and disrupts nucleotide metabolism to kill rapidly dividing cancer cells. Used for Pancreatic cancer, Gastric cancer, Biliary tract cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}